RISEDRONATE SODIUM
Clinical safety rating: avoid
Contraindicated (not allowed)
Bisphosphonate that inhibits osteoclast-mediated bone resorption by binding to hydroxyapatite crystals in bone, preventing osteoclast attachment and inducing osteoclast apoptosis.
| Metabolism | Not metabolized; eliminated unchanged primarily by renal excretion via glomerular filtration and tubular secretion. |
| Excretion | Renal excretion (unchanged, via glomerular filtration and active tubular secretion): 50-65% of absorbed dose. Fecal excretion: minor, <5% as unabsorbed drug. Biliary excretion: negligible. |
| Half-life | Terminal elimination half-life: 480 hours (20 days) due to slow release from bone; clinical context: supports once-weekly dosing for osteoporosis. |
| Protein binding | ~24% bound to plasma proteins, primarily albumin. Binding is concentration-independent and low affinity. |
| Volume of Distribution | Steady-state Vd: 6.3 L/kg; extensive distribution into bone mineral (hydroxyapatite) and low soft tissue penetration. |
| Bioavailability | Oral: 0.63% (fasted state, mean; range 0.5–0.8%). Food, calcium, and iron significantly reduce absorption; must be taken with plain water on empty stomach. |
| Onset of Action | Oral: Reduction of bone resorption markers observed within 14 days; maximal effect on bone turnover in 3-6 months. IV: Not clinically applicable. |
| Duration of Action | Bone turnover suppression persists for up to 12 months after discontinuation due to bone binding; clinical note: residual effects require consideration when sequencing antiresorptive therapy. |
35 mg orally once weekly or 5 mg orally once daily, taken at least 30 minutes before the first food or beverage of the day with 6-8 ounces of plain water. For Paget disease: 30 mg orally once daily for 2 months.
| Dosage form | TABLET, DELAYED RELEASE |
| Renal impairment | Contraindicated if creatinine clearance <30 mL/min. For CrCl 30-59 mL/min: no dose adjustment needed. For CrCl <30 mL/min: not recommended. |
| Liver impairment | No specific guidelines; hepatic impairment does not significantly alter risedronate pharmacokinetics. Use with caution in severe hepatic impairment due to potential comorbidities. |
| Pediatric use | Safety and efficacy not established in children <18 years; not recommended. |
| Geriatric use | No specific dose adjustment required for age alone; ensure adequate calcium and vitamin D intake, monitor renal function as age-related decline may occur. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Calcium supplements and other oral medications can interfere with absorption Risk of esophageal irritation and osteonecrosis of the jaw.
| Breastfeeding | Excretion in human milk is unknown; however, bisphosphonates are poorly absorbed orally. M/P ratio not available. Risk to nursing infant is likely low due to low milk concentrations and poor absorption. Caution is advised; consider benefit-risk. |
| Teratogenic Risk | Risedronate sodium is pregnancy category C. In animal studies, maternal toxicity at high doses resulted in fetal skeletal abnormalities and reduced fetal weight. There are no adequate and well-controlled studies in pregnant women. First trimester: theoretical risk of bisphosphonate incorporation into fetal bone matrix; second and third trimesters: potential for fetal bone abnormalities and neonatal hypocalcemia. Use only if clearly needed. |
■ FDA Black Box Warning
None.
| Common Effects | Paget's disease |
| Serious Effects |
["Hypersensitivity to risedronate or any component of the formulation","Hypocalcemia","Inability to stand or sit upright for at least 30 minutes","Severe renal impairment (CrCl < 30 mL/min)"]
| Precautions | ["Risk of atypical femur fractures","Osteonecrosis of the jaw, especially with invasive dental procedures","Severe musculoskeletal pain","Renal impairment: not recommended in patients with CrCl < 30 mL/min","Electrolyte disturbances: hypocalcemia must be corrected before initiation"] |
Loading safety data…
| Fetal Monitoring | Monitor serum calcium, phosphate, and magnesium levels. Assess bone mineral density. Monitor fetal growth and development via ultrasound if used during pregnancy. Watch for maternal hypocalcemia. |
| Fertility Effects | No significant adverse effects on fertility reported in animal studies. Human data limited; theoretical risk due to bone metabolism alterations but generally considered minimal. |